FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 338:1074-1075 April 9, 1998 Number 15 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

To the Editor: A major goal of antiretroviral therapy for human immunodeficiency virus (HIV) infection should be to keep the viral load undetectable or at least suppressed as fully as possible.^1,2 For patients with detectable viral loads, changes in medication have been advocated on the basis of studies demonstrating that viral load is a surrogate marker for the clinical progression of HIV infection. However, patients who have persistently elevated viral loads despite treatment with highly active antiretroviral agents (generally a protease inhibitor and two reverse-transcriptase inhibitors) have few therapeutic options. There are a limited number of drugs available, and medication . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Hadad, N., Levy, R., Schlaeffer, F., Riesenberg, K. (2007). Direct Effect of Human Immunodeficiency Virus Protease Inhibitors on Neutrophil Function and Apoptosis via Calpain Inhibition. CVI 14: 1515-1521 [Abstract] [Full Text]  
• Goldie, S. J., Yazdanpanah, Y., Losina, E., Weinstein, M. C., Anglaret, X., Walensky, R. P., Hsu, H. E., Kimmel, A., Holmes, C., Kaplan, J. E., Freedberg, K. A. (2006). Cost-Effectiveness of HIV Treatment in Resource-Poor Settings -- The Case of Cote d'Ivoire. NEJM 355: 1141-1153 [Abstract] [Full Text]  
• Chu, H., Gange, S. J., Yamashita, T. E., Hoover, D. R., Chmiel, J. S., Margolick, J. B., Jacobson, L. P. (2005). Individual Variation in CD4 Cell Count Trajectory among Human Immunodeficiency Virus-infected Men and Women on Long-term Highly Active Antiretroviral Therapy: An Application using a Bayesian Random Change-Point Model. Am J Epidemiol 162: 787-797 [Abstract] [Full Text]  
• Equils, O., Shapiro, A., Madak, Z., Liu, C., Lu, D. (2004). Human Immunodeficiency Virus Type 1 Protease Inhibitors Block Toll-Like Receptor 2 (TLR2)- and TLR4-Induced NF-{kappa}B Activation. Antimicrob. Agents Chemother. 48: 3905-3911 [Abstract] [Full Text]  
• Liuzzi, G. M., Mastroianni, C. M., Latronico, T., Mengoni, F., Fasano, A., Lichtner, M., Vullo, V., Riccio, P. (2004). Anti-HIV drugs decrease the expression of matrix metalloproteinases in astrocytes and microglia. Brain 127: 398-407 [Abstract] [Full Text]  
• Pati, S., Pelser, C. B., Dufraine, J., Bryant, J. L., Reitz, M. S. Jr, Weichold, F. F. (2002). Antitumorigenic effects of HIV protease inhibitor ritonavir: inhibition of Kaposi sarcoma. Blood 99: 3771-3779 [Abstract] [Full Text]  
• Goldie, S. J., Kaplan, J. E., Losina, E., Weinstein, M. C., Paltiel, A. D., Seage III, G. R., Craven, D. E., Kimmel, A. D., Zhang, H., Cohen, C. J., Freedberg, K. A. (2002). Prophylaxis for Human Immunodeficiency Virus-Related Pneumocystis carinii Pneumonia: Using Simulation Modeling to Inform Clinical Guidelines. Arch Intern Med 162: 921-928 [Abstract] [Full Text]  
• Gruber, A., Wheat, J. C., Kuhen, K. L., Looney, D. J., Wong-Staal, F. (2001). Differential Effects of HIV-1 Protease Inhibitors on Dendritic Cell Immunophenotype and Function. J. Biol. Chem. 276: 47840-47843 [Abstract] [Full Text]  
• Lu, W., Andrieu, J.-M. (2001). In Vitro Human Immunodeficiency Virus Eradication by Autologous CD8+ T Cells Expanded with Inactivated-Virus-Pulsed Dendritic Cells. J. Virol. 75: 8949-8956 [Abstract] [Full Text]  
• Lu, W., Achour, A., Arlie, M., Cao, L., Andrieu, J.-M. (2001). Enhanced Dendritic Cell-Driven Proliferation and Anti-HIV Activity of CD8+ T Cells by a New Phenothiazine Derivative, Aminoperazine. J. Immunol. 167: 2929-2935 [Abstract] [Full Text]  
• Phenix, B. N., Lum, J. J., Nie, Z., Sanchez-Dardon, J., Badley, A. D. (2001). Antiapoptotic mechanism of HIV protease inhibitors: preventing mitochondrial transmembrane potential loss. Blood 98: 1078-1085 [Abstract] [Full Text]  
• Bohler, T., Debatin, K.-M., Wintergerst, U., Lu, W., Andrieu, J.-M. (2001). T-cell apoptosis in HIV-1-infected individuals receiving highly active antiretroviral therapy. Blood 97: 1898-1901 [Full Text]  
• Badley, A. D., Pilon, A. A., Landay, A., Lynch, D. H. (2000). Mechanisms of HIV-associated lymphocyte apoptosis. Blood 96: 2951-2964 [Abstract] [Full Text]  
• Grabar, S., Moing, V. L., Goujard, C., Leport, C., Kazatchkine, M. D., Costagliola, D., Weiss, L. (2000). Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral Therapy. ANN INTERN MED 133: 401-410 [Abstract] [Full Text]  
• Lu, W., Andrieu, J.-M. (2000). HIV protease inhibitors restore impaired T-cell proliferative response in vivo and in vitro: a viral-suppression-independent mechanism. Blood 96: 250-258 [Abstract] [Full Text]  
• Schwartz, S. A., Nair, M. P. N. (1999). Current Concepts in Human Immunodeficiency Virus Infection and AIDS. CVI 6: 295-305 [Full Text]